Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

Clinical trial NCT05142722 · COMPLETED

Trial details

NCT number: NCT05142722
Sponsor: NewAmsterdam Pharma
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Dyslipidemias High Cholesterol Hypercholesterolemia Familial Hypercholesterolemia Atherosclerotic Cardiovascular Disease

Start date: 2021-12-15
Primary completion: 2024-09-26
Enrollment: 2530

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.